New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

and diabetic macular edema (DME). 2 The company has also filed an application with the FDA for the use of pre-filled syringes (PFS) of high-dose aflibercept with the US. Approval and launch of these ...

Individuals who developed vs did not develop postoperative delirium exhibited thicker preoperative macular thickness in the right eye. HealthDay News — In older patients undergoing surgery ...

Follow-up continued until an event, death, or study end in 2019. Among 8873 patients with diabetic macular edema treated using intravitreal anti-vascular endothelial growth factor (VEGF) therapy ...

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts. SS-OCTA offers distinct advantages over ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...